William Blair Investment Management LLC lifted its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 12.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,826,079 shares of the biopharmaceutical company’s stock after purchasing an additional 958,414 shares during the period. William Blair Investment Management LLC owned about 5.39% of Horizon Pharma worth $128,861,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advantage Investment Management LLC raised its stake in shares of Horizon Pharma by 164.8% during the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 4,900 shares in the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Horizon Pharma during the 4th quarter worth approximately $160,000. K2 Principal Fund L.P. raised its stake in shares of Horizon Pharma by 126.1% during the 4th quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 53,574 shares in the last quarter. Zeke Capital Advisors LLC bought a new position in shares of Horizon Pharma during the 4th quarter worth approximately $167,000. Finally, Brown Advisory Inc. bought a new position in shares of Horizon Pharma during the 3rd quarter worth approximately $145,000. Hedge funds and other institutional investors own 86.75% of the company’s stock.

A number of research analysts have issued reports on the stock. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Monday, January 8th. UBS set a $20.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, March 1st. BidaskClub upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 3rd. Finally, ValuEngine lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $18.64.

Horizon Pharma stock opened at $14.51 on Thursday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.54 and a current ratio of 1.63. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $16.02. The stock has a market cap of $2,397.78, a P/E ratio of -5.78, a price-to-earnings-growth ratio of 0.62 and a beta of 1.34.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.07. The firm had revenue of $274.22 million for the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.64 earnings per share. equities research analysts expect that Horizon Pharma PLC will post 1.43 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “William Blair Investment Management LLC Increases Stake in Horizon Pharma PLC (HZNP)” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/03/22/william-blair-investment-management-llc-increases-stake-in-horizon-pharma-plc-hznp.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.